Choline transporter gene variation is associated with attention-deficit hyperactivity disorder / Brett A. ENGLISH in Journal of Neurodevelopmental Disorders, 1-4 (December 2009)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 1-4 (December 2009) . - p.252-63 Titre : Choline transporter gene variation is associated with attention-deficit hyperactivity disorder Type de document : texte imprimé Auteurs : Brett A. ENGLISH, Auteur ; Maureen K. HAHN, Auteur ; Ian R. GIZER, Auteur ; Michelle MAZEI-ROBISON, Auteur ; Angela STEELE, Auteur ; Daniel M. KURNIK, Auteur ; Mark A. STEIN, Auteur ; Irwin D. WALDMAN, Auteur ; Randy D. BLAKELY, Auteur Article en page(s) : p.252-63 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The neurotransmitter acetylcholine (ACh) plays a critical role in brain circuits mediating motor control, attention, learning and memory. Cholinergic dysfunction is associated with multiple brain disorders including Alzheimer's Disease, addiction, schizophrenia and Attention-Deficit Hyperactivity Disorder (ADHD). The presynaptic choline transporter (CHT, SLC5A7) is the major, rate-limiting determinant of ACh production in the brain and periphery and is consequently upregulated during tasks that require sustained attention. Given the contribution of central cholinergic circuits to the control of movement and attention, we hypothesized that functional CHT gene variants might impact risk for ADHD. We performed a case-control study, followed by family-based association tests on a separate cohort, of two purportedly functional CHT polymorphisms (coding variant Ile89Val (rs1013940) and a genomic SNP 3' of the CHT gene (rs333229), affording both a replication sample and opportunities to reduce potential population stratification biases. Initial genotyping of pediatric ADHD subjects for two purportedly functional CHT alleles revealed a 2-3 fold elevation of the Val89 allele (n = 100; P = 0.02) relative to healthy controls, as well as a significant decrease of the 3'SNP minor allele in Caucasian male subjects (n = 60; P = 0.004). In family based association tests, we found significant overtransmission of the Val89 variant to children with a Combined subtype diagnosis (OR = 3.16; P = 0.01), with an increased Odds Ratio for a haplotype comprising both minor alleles. These studies show evidence of cholinergic deficits in ADHD, particularly for subjects with the Combined subtype, and, if replicated, may encourage further consideration of cholinergic agonist therapy in the disorder. En ligne : http://dx.doi.org/10.1007/s11689-009-9033-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=341 [article] Choline transporter gene variation is associated with attention-deficit hyperactivity disorder [texte imprimé] / Brett A. ENGLISH, Auteur ; Maureen K. HAHN, Auteur ; Ian R. GIZER, Auteur ; Michelle MAZEI-ROBISON, Auteur ; Angela STEELE, Auteur ; Daniel M. KURNIK, Auteur ; Mark A. STEIN, Auteur ; Irwin D. WALDMAN, Auteur ; Randy D. BLAKELY, Auteur . - p.252-63. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 1-4 (December 2009) . - p.252-63 Index. décimale : PER Périodiques Résumé : The neurotransmitter acetylcholine (ACh) plays a critical role in brain circuits mediating motor control, attention, learning and memory. Cholinergic dysfunction is associated with multiple brain disorders including Alzheimer's Disease, addiction, schizophrenia and Attention-Deficit Hyperactivity Disorder (ADHD). The presynaptic choline transporter (CHT, SLC5A7) is the major, rate-limiting determinant of ACh production in the brain and periphery and is consequently upregulated during tasks that require sustained attention. Given the contribution of central cholinergic circuits to the control of movement and attention, we hypothesized that functional CHT gene variants might impact risk for ADHD. We performed a case-control study, followed by family-based association tests on a separate cohort, of two purportedly functional CHT polymorphisms (coding variant Ile89Val (rs1013940) and a genomic SNP 3' of the CHT gene (rs333229), affording both a replication sample and opportunities to reduce potential population stratification biases. Initial genotyping of pediatric ADHD subjects for two purportedly functional CHT alleles revealed a 2-3 fold elevation of the Val89 allele (n = 100; P = 0.02) relative to healthy controls, as well as a significant decrease of the 3'SNP minor allele in Caucasian male subjects (n = 60; P = 0.004). In family based association tests, we found significant overtransmission of the Val89 variant to children with a Combined subtype diagnosis (OR = 3.16; P = 0.01), with an increased Odds Ratio for a haplotype comprising both minor alleles. These studies show evidence of cholinergic deficits in ADHD, particularly for subjects with the Combined subtype, and, if replicated, may encourage further consideration of cholinergic agonist therapy in the disorder. En ligne : http://dx.doi.org/10.1007/s11689-009-9033-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=341

Commentary: Does helping mothers with ADHD in multiplex families help children? Reflections on Jans et al. (2015) / Mark A. STEIN in Journal of Child Psychology and Psychiatry, 56-12 (December 2015)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 56-12 (December 2015) . - p.1314-1315 Titre : Commentary: Does helping mothers with ADHD in multiplex families help children? Reflections on Jans et al. (2015) Type de document : texte imprimé Auteurs : Mark A. STEIN, Auteur Article en page(s) : p.1314-1315 Langues : Anglais (eng) Mots-clés : ADHD  parent training  methylphenidate  multiplex families Index. décimale : PER Périodiques Résumé : Reflecting on the accompanying article by Jans et al., we draw the following thoughts. Future research on multiplex ADHD families is needed to elucidate mechanisms, timing, and a sequencing of interventions, preferably in treatment naïve participants. Furthermore, in addition to symptom measures, it is likely that multi-informant measures of functional impairments such as parenting and parent-child observations may help elucidate the complex mechanisms linking maternal and child ADHD, and eventually lead to more targeted, efficient, and feasible prevention and intervention strategies. En ligne : http://dx.doi.org/10.1111/jcpp.12454 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=273 [article] Commentary: Does helping mothers with ADHD in multiplex families help children? Reflections on Jans et al. (2015) [texte imprimé] / Mark A. STEIN, Auteur . - p.1314-1315. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 56-12 (December 2015) . - p.1314-1315 Mots-clés : ADHD  parent training  methylphenidate  multiplex families Index. décimale : PER Périodiques Résumé : Reflecting on the accompanying article by Jans et al., we draw the following thoughts. Future research on multiplex ADHD families is needed to elucidate mechanisms, timing, and a sequencing of interventions, preferably in treatment naïve participants. Furthermore, in addition to symptom measures, it is likely that multi-informant measures of functional impairments such as parenting and parent-child observations may help elucidate the complex mechanisms linking maternal and child ADHD, and eventually lead to more targeted, efficient, and feasible prevention and intervention strategies. En ligne : http://dx.doi.org/10.1111/jcpp.12454 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=273

Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016) / Mark A. STEIN in Journal of Child Psychology and Psychiatry, 57-6 (June 2016)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 57-6 (June 2016) . - p.770-771 Titre : Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016) Type de document : texte imprimé Auteurs : Mark A. STEIN, Auteur ; Steven M. SNYDER, Auteur ; Thomas A. RUGINO, Auteur ; Mady HORNIG, Auteur Article en page(s) : p.770-771 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Neuropsychiatric EEG-Based ADHD Assessment Aid (NEBA) is an EEG-based device designed to aid in the diagnostic process for ADHD by identifying individuals less likely to have ADHD by virtue of a lower theta/beta ratio. In using NEBA as an example, the Arns et al. commentary misstates the purpose of NEBA, which is to widen the differential rather than to make the diagnosis. Arns et al. caution about missing an ADHD diagnosis, but fail to mention the impact of overdiagnosis. If we are to advance our knowledge of the etiology and pathophysiology of ADHD, as well as develop tailored treatments and ultimately improve outcomes for ADHD, then biomarkers and objective assessment aids such as NEBA are needed to improve and refine diagnostic accuracy beyond symptom description and clinical history. En ligne : http://dx.doi.org/10.1111/jcpp.12534 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=289 [article] Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016) [texte imprimé] / Mark A. STEIN, Auteur ; Steven M. SNYDER, Auteur ; Thomas A. RUGINO, Auteur ; Mady HORNIG, Auteur . - p.770-771. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 57-6 (June 2016) . - p.770-771 Index. décimale : PER Périodiques Résumé : Neuropsychiatric EEG-Based ADHD Assessment Aid (NEBA) is an EEG-based device designed to aid in the diagnostic process for ADHD by identifying individuals less likely to have ADHD by virtue of a lower theta/beta ratio. In using NEBA as an example, the Arns et al. commentary misstates the purpose of NEBA, which is to widen the differential rather than to make the diagnosis. Arns et al. caution about missing an ADHD diagnosis, but fail to mention the impact of overdiagnosis. If we are to advance our knowledge of the etiology and pathophysiology of ADHD, as well as develop tailored treatments and ultimately improve outcomes for ADHD, then biomarkers and objective assessment aids such as NEBA are needed to improve and refine diagnostic accuracy beyond symptom description and clinical history. En ligne : http://dx.doi.org/10.1111/jcpp.12534 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=289

Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder / Anne-Claude V. BÉDARD in Journal of Child Psychology and Psychiatry, 56-1 (January 2015)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 56-1 (January 2015) . - p.40-48 Titre : Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder Type de document : texte imprimé Auteurs : Anne-Claude V. BÉDARD, Auteur ; Mark A. STEIN, Auteur ; Jeffrey M. HALPERIN, Auteur ; Beth KRONE, Auteur ; Estrella RAJWAN, Auteur ; Jeffrey H. NEWCORN, Auteur Article en page(s) : p.40-48 Langues : Anglais (eng) Mots-clés : Attention-deficit/hyperactivity disorder  atomoxetine  methylphenidate  attention  vigilance Index. décimale : PER Périodiques Résumé : Background This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with attention-deficit/hyperactivity disorder (ADHD). It was hypothesized that performance would be improved by both treatments, but response profiles would differ because the medications work via different mechanisms. Methods One hundred and two youth (77 male; mean age = 10.5 ± 2.7 years) with ADHD received ATX (1.4 ± 0.5 mg/kg) and MPH (52.4 ± 16.6 mg) in a randomized, double-blind, crossover design. Medication was titrated in 4–6-week blocks separated by a 2-week placebo washout. Inhibitory control and attention measures were obtained at baseline, following washout, and at the end of each treatment using Conners' Continuous Performance Test II (CPT-II), which provided age-adjusted T-scores for reaction time (RT), reaction time variability (RT variability), and errors. Repeated-measures analyses of variance were performed, with Time (premedication, postmedication) and Treatment type (ATX, MPH) entered as within-subject factors. Data from the two treatment blocks were checked for order effects and combined if order effects were not present. Clinical trial registration: Clinicaltrials.gov: NCT00183391. Results Main effects for Time on RT (p = .03), RTSD (p = .001), and omission errors (p = .01) were significant. A significant Drug × Time interaction indicated that MPH improved RT, RTSD, and omission errors more than ATX (p < .05). Changes in performance with treatment did not correlate with changes in ADHD symptoms. Conclusions MPH has greater effects than ATX on CPT measures of sustained attention in youth with ADHD. However, the dissociation of cognitive and behavioral change with treatment indicates that CPT measures cannot be considered proxies for symptomatic improvement. Further research on the dissociation of cognitive and behavioral endpoints for ADHD is indicated. En ligne : http://dx.doi.org/10.1111/jcpp.12272 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=259 [article] Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder [texte imprimé] / Anne-Claude V. BÉDARD, Auteur ; Mark A. STEIN, Auteur ; Jeffrey M. HALPERIN, Auteur ; Beth KRONE, Auteur ; Estrella RAJWAN, Auteur ; Jeffrey H. NEWCORN, Auteur . - p.40-48. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 56-1 (January 2015) . - p.40-48 Mots-clés : Attention-deficit/hyperactivity disorder  atomoxetine  methylphenidate  attention  vigilance Index. décimale : PER Périodiques Résumé : Background This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with attention-deficit/hyperactivity disorder (ADHD). It was hypothesized that performance would be improved by both treatments, but response profiles would differ because the medications work via different mechanisms. Methods One hundred and two youth (77 male; mean age = 10.5 ± 2.7 years) with ADHD received ATX (1.4 ± 0.5 mg/kg) and MPH (52.4 ± 16.6 mg) in a randomized, double-blind, crossover design. Medication was titrated in 4–6-week blocks separated by a 2-week placebo washout. Inhibitory control and attention measures were obtained at baseline, following washout, and at the end of each treatment using Conners' Continuous Performance Test II (CPT-II), which provided age-adjusted T-scores for reaction time (RT), reaction time variability (RT variability), and errors. Repeated-measures analyses of variance were performed, with Time (premedication, postmedication) and Treatment type (ATX, MPH) entered as within-subject factors. Data from the two treatment blocks were checked for order effects and combined if order effects were not present. Clinical trial registration: Clinicaltrials.gov: NCT00183391. Results Main effects for Time on RT (p = .03), RTSD (p = .001), and omission errors (p = .01) were significant. A significant Drug × Time interaction indicated that MPH improved RT, RTSD, and omission errors more than ATX (p < .05). Changes in performance with treatment did not correlate with changes in ADHD symptoms. Conclusions MPH has greater effects than ATX on CPT measures of sustained attention in youth with ADHD. However, the dissociation of cognitive and behavioral change with treatment indicates that CPT measures cannot be considered proxies for symptomatic improvement. Further research on the dissociation of cognitive and behavioral endpoints for ADHD is indicated. En ligne : http://dx.doi.org/10.1111/jcpp.12272 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=259

Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study / Soo-Jeong KIM in Journal of Autism and Developmental Disorders, 47-8 (August 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-8 (August 2017) . - p.2307-2313 Titre : Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study Type de document : texte imprimé Auteurs : Soo-Jeong KIM, Auteur ; Sophia SHONKA, Auteur ; William P. FRENCH, Auteur ; Jennifer STRICKLAND, Auteur ; Lindsey MILLER, Auteur ; Mark A. STEIN, Auteur Article en page(s) : p.2307-2313 Langues : Anglais (eng) Mots-clés : Attention deficit hyperactivity disorder  ADHD  Autism spectrum disorder  ASD  Methylphenidate Index. décimale : PER Périodiques Résumé : Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy. En ligne : https://doi.org/10.1007/s10803-017-3125-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 [article] Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study [texte imprimé] / Soo-Jeong KIM, Auteur ; Sophia SHONKA, Auteur ; William P. FRENCH, Auteur ; Jennifer STRICKLAND, Auteur ; Lindsey MILLER, Auteur ; Mark A. STEIN, Auteur . - p.2307-2313. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-8 (August 2017) . - p.2307-2313 Mots-clés : Attention deficit hyperactivity disorder  ADHD  Autism spectrum disorder  ASD  Methylphenidate Index. décimale : PER Périodiques Résumé : Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy. En ligne : https://doi.org/10.1007/s10803-017-3125-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314

Editorial Perspective: COVID-19, ADHD management and telehealth: uncertain path / Mark A. STEIN in Journal of Child Psychology and Psychiatry, 63-7 (July 2022)  

Permalink

Effects of Maternal Stimulant Medication on Observed Parenting in Mother-Child Dyads With Attention-Deficit/Hyperactivity Disorder / Andrea CHRONIS-TUSCANO in Journal of Clinical Child & Adolescent Psychology, 39-4 (July-August 2010)  

Permalink

Research Review: Pharmacological and non-pharmacological treatments for adolescents with attention deficit/hyperactivity disorder - a systematic review of the literature / Margaret H. SIBLEY in Journal of Child Psychology and Psychiatry, 66-1 (January 2025)  

Permalink

---

1 (1 - 8 / 8) Par page : 25 50 100 200